Eton Pharmaceuticals (ETON) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.50
- Estimate
- $0.37
- Surprise
- +35.1%
- Revenue (period 2026-09-30)
- $57.9M
- Score at report (before → after)
- 6.5 → 6.5/10
Revenue source: xbrl.
How the report landed
Eton Pharmaceuticals (ETON) beat the $0.37 estimate with adjusted EPS of $0.50 — a large 35.1% upside surprise. TrendMatrix's engine moved from Hold (6.5/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ETON Buy (Wait) at 6.9/10.
1 of the last 4 quarters beat the estimate; this quarter's +35.1% surprise compares with a +15.1% four-quarter average. Next scheduled report: 2027-03-25.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.5 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Thin upside margin: 7.6%
- News modifier capped: WAIT cannot upgrade to NOW via sentiment alone
- Reward/Risk 0.5:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $56.46
- Entry target
- $53.43
- Price target
- $60.77
- Stop
- $49.69
- Upside to target
- +7.6%
- Reward-to-risk
- 0.5:1
The stock trades at 36.7× trailing but 22.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
ETON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.61B
- P/E (fwd)
- 22.1
- P/E (ttm)
- 36.7
- 52-week range
- $14.27–$66.37
- Off 52-week high
- 14.9%
- RSI (14)
- 66
- Volume vs avg
- 2.76×
- Score today
- 6.9/10